Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

130.50 -0.49 (-0.37%)
Streaming Delayed Price Updated: 3:07 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,997,605
Open 131.68
Bid (Size) 130.50 (2)
Ask (Size) 130.51 (2)
Prev. Close 130.99
Today's Range 130.48 - 132.79
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Performance Comparison: Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets

Performance

YTD
+15.25%
+15.25%
1 Month
+2.81%
+2.81%
3 Month
+2.46%
+2.46%
6 Month
+27.10%
+27.10%
1 Year
+13.99%
+13.99%

More News

Read More
5 Stocks Powering The Dow ETF Year To Date
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches
Via InvestorPlace
Check Out What Whales Are Doing With MRK
Via Benzinga
Market Analysis: Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
Via Talk Markets
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
From Merck & Co., Inc.
Via Business Wire
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Via Benzinga
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
From Merck & Co., Inc.
Via Business Wire
Healthcare And Biotech Investing 101: What You Need To Know.
Via Talk Markets
Topics Stocks
Exposures US Equities
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Via Benzinga
3 Biotech Stocks to Sell in May Before They Crash & Burn
Via InvestorPlace
The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
From Merck & Co., Inc.
Via Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Via FinancialNewsMedia
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Via Benzinga
Topics Economy
Exposures Economy
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
A Look At Pharma ETFs Post Q1 Earnings
Via Talk Markets
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.